Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.

Also called NCT06488105

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 130 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06488105
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06488105. Randomized; no masking; primary purpose prevention. Start 2024-08-05 (actual); primary completion 2027-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
Acronym
EMERALD RCT
Condition
Lipid Disorder
Condition
Hypercholesterolemia
Condition
Cardiovascular Diseases
Condition
Atherosclerosis
Intervention (Drug)
Statin (rosuvastatin 10 or 40 mg daily, depending on risk)
Intervention (Behavioral)
Healthy Lifestyle Counseling
Intervention (Other)
Outpatient Followup
Lead sponsor
Wake Forest University Health Sciences (class: other)
Collaborator
National Institutes of Health (NIH) (class: US National Institutes of Health)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct06488105
Content hash
af750d96293d700417f9bd87cd04f1dfee597532600fe4ed27beebd1ccedbb62